SBIR/STTR Research Award

NEW LABELING REAGENTS FOR GENETIC ANALYSIS

Award identifier adde9f5d2fc0cf0a602850ccff19fd9408b73d7a42cab0a8e73b7b40e652d496Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,982

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MARKER GENE TECHNOLOGIES INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
LDL9MLRAHY77
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project aims to investigate the feasibility of developing new, sensitive, accurate, and reliable detection methods for genomic DNA or RNA samples that are essential for genomic microarray analysis. If successful, the proposed research will help provide breakthroughs needed to advance the promising medical uses of genomic analysis to determine the pattern of gene expression in live cell assays. In Phase I of this project, Marker Gene Technologies proposes to establish the feasibility of the technology by preparing new labeling reagents and systems capable of directly modifying DNA or RNA oligomers for ultrasensitive fluorescence or chemiluminescent detection. These labeling reagents will be assayed in vitro for their ability to monitor gene expression events in response to biological effects on cell function and to monitor the change in gene expression upon application of drugs and bioactive compounds in a cell-specific manner. In Phase II, these and additional detection reagents and methods will be further tested in a variety of pre-clinical applications for genomic expression analysis combined with drug application. PROPOSED COMMERCIAL APPLICATION: The success of this project opens up enormous commercial possibilities in the fields of medical intervention in genetic diseases, genetic screening of new proteins and drugs in cell-culture systems, and new anti-bacterial and anti-viral agent discovery. In addition, it contributes new information and techniques for basic cell-biology research, and the labeling reagents and techniques produced can be marketed for these research and commercial uses.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

17 SBIR/STTR records share this UEI (1996–2017). Reported award amounts total $5,601,975. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.